BMY vs CDP · P/E 17, rev $48.19B vs P/E 24, rev $398.0M
Bristol-Myers Squibb Company (BMY) versus COPT Defense Properties (CDP) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Chris Boerner.
COPT Defense Properties (CDP) is a reit - office company listed on NYSE.
Latest reported BMY revenue for 2025-12-31 was $48.19B. Net income was $7.05B. Revenue was down 0.2% from 2024-12-31 to 2025-12-31. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Latest reported CDP revenue for 2026-06-30 was $398.0M. Net income was $88.7M. Revenue was up 98.4% from 2026-03-31 to 2026-06-30. CDP currently screens at market cap $3.84B and trailing P/E 24.3.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. CDP currently screens at market cap $3.84B and trailing P/E 24.3.
Not investment advice. Open the BMY and CDP stock pages for the full models.
Not investment advice.